During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

For traditional cellular therapies like chimeric antigen receptor T-cell and NK-cell infusions, this "preconditioning" is vital to clear a biological path, removing endogenous cells that would ...

SLNB remains a key staging procedure in clinically node-negative melanoma and provides prognostic information that can guide adjuvant therapy discussions. Current NCCN guidelines recommend discussing ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

The study concludes that at-home self-sampling is a "people-centered" approach that can reduce the burden on strained healthcare systems and address deep-seated barriers like mistrust and ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

IDH -mutant gliomas represent a rare subset of brain tumors, affecting approximately 12% to 20% of adult patients with glioma ...